401 related articles for article (PubMed ID: 27468203)
21. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
22. Authors' response: Metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents.
Wu CY; Chen HP
Gut; 2013 Jun; 62(6):952. PubMed ID: 23355550
[No Abstract] [Full Text] [Related]
23. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Chan KM; Kuo CF; Hsu JT; Chiou MJ; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Lee WC
Liver Int; 2017 Mar; 37(3):434-441. PubMed ID: 27775209
[TBL] [Abstract][Full Text] [Related]
24. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
25. Diabetes medications and risk of HCC.
Plaz Torres MC; Jaffe A; Perry R; Marabotto E; Strazzabosco M; Giannini EG
Hepatology; 2022 Dec; 76(6):1880-1897. PubMed ID: 35239194
[TBL] [Abstract][Full Text] [Related]
26. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Kasmari AJ; Welch A; Liu G; Leslie D; McGarrity T; Riley T
Am J Med; 2017 Jun; 130(6):746.e1-746.e7. PubMed ID: 28109969
[TBL] [Abstract][Full Text] [Related]
27. Metformin and risk of hepatocellular carcinoma: are statins the missing link?
Singh S; Singh PP
Gut; 2013 Jun; 62(6):951-2. PubMed ID: 23263525
[No Abstract] [Full Text] [Related]
28. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
[TBL] [Abstract][Full Text] [Related]
29. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.
Huynh DJ; Renelus BD; Jamorabo DS
BMC Gastroenterol; 2023 Dec; 23(1):450. PubMed ID: 38114915
[TBL] [Abstract][Full Text] [Related]
30. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Seo YS; Kim YJ; Kim MS; Suh KS; Kim SB; Han CJ; Kim YJ; Jang WI; Kang SH; Tchoe HJ; Park CM; Jo AJ; Kim HJ; Choi JA; Choi HJ; Polak MN; Ko MJ
Medicine (Baltimore); 2016 Apr; 95(17):e3527. PubMed ID: 27124061
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.
Cauchy F; Mebarki M; Albuquerque M; Laouirem S; Rautou PE; Soubrane O; Raymond E; Bedossa P; Paradis V
Gut; 2015 Sep; 64(9):1498-500. PubMed ID: 26123027
[No Abstract] [Full Text] [Related]
32. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.
Murff HJ; Roumie CL; Greevy RA; Hackstadt AJ; McGowan LED; Hung AM; Grijalva CG; Griffin MR
Cancer Causes Control; 2018 Sep; 29(9):823-832. PubMed ID: 30022336
[TBL] [Abstract][Full Text] [Related]
33. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
Li Q; Xu H; Sui C; Zhang H
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101781. PubMed ID: 34332136
[TBL] [Abstract][Full Text] [Related]
34. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
35. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.
Singh MK; Das BK; Choudhary S; Gupta D; Patil UK
Biomed Pharmacother; 2018 Oct; 106():991-1002. PubMed ID: 30119271
[TBL] [Abstract][Full Text] [Related]
36. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
Lee MS; Hsu CC; Wahlqvist ML; Tsai HN; Chang YH; Huang YC
BMC Cancer; 2011 Jan; 11():20. PubMed ID: 21241523
[TBL] [Abstract][Full Text] [Related]
37. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
38. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Saito T; Chiba T; Yuki K; Zen Y; Oshima M; Koide S; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Tada M; Kanai F; Takiguchi Y; Iwama A; Yokosuka O
PLoS One; 2013; 8(7):e70010. PubMed ID: 23922888
[TBL] [Abstract][Full Text] [Related]
39. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.
Chen TM; Lin CC; Huang PT; Wen CF
J Gastroenterol Hepatol; 2011 May; 26(5):858-65. PubMed ID: 21251068
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
